Letter to the Editor
Tirbanibulin ointment: A new effective and safe treatment of recalcitrant viral warts
Tirbanibulina: un nuevo tratamiento efectivo y seguro para verrugas víricas recalcitrantes
Read
3
Timeswas read the article
0
Total PDF
3
Total HTML
Share statistics
array:22 [ "pii" => "S1138359324000881" "issn" => "11383593" "doi" => "10.1016/j.semerg.2024.102278" "estado" => "S250" "fechaPublicacion" => "2024-11-01" "aid" => "102278" "copyright" => "Sociedad Española de Médicos de Atención Primaria (SEMERGEN)" "copyrightAnyo" => "2024" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "itemSiguiente" => array:17 [ "pii" => "S1138359324000856" "issn" => "11383593" "doi" => "10.1016/j.semerg.2024.102275" "estado" => "S250" "fechaPublicacion" => "2024-11-01" "aid" => "102275" "copyright" => "Sociedad Española de Médicos de Atención Primaria (SEMERGEN)" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:9 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Letter to the Editor</span>" "titulo" => "Opportunities of digital health in primary care" "tienePdf" => "en" "tieneTextoCompleto" => "en" "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Oportunidades de la sanidad digital en la atención primaria" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "R. Cobos-Campos, A. Sáez de Lafuente, I. Pérez-Llanos" "autores" => array:3 [ 0 => array:2 [ "nombre" => "R." "apellidos" => "Cobos-Campos" ] 1 => array:2 [ "nombre" => "A." "apellidos" => "Sáez de Lafuente" ] 2 => array:2 [ "nombre" => "I." "apellidos" => "Pérez-Llanos" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1138359324000856?idApp=UINPBA00004N" "url" => "/11383593/0000005000000008/v8_202409230945/S1138359324000856/v8_202409230945/en/main.assets" ] "itemAnterior" => array:17 [ "pii" => "S1138359324000893" "issn" => "11383593" "doi" => "10.1016/j.semerg.2024.102279" "estado" => "S250" "fechaPublicacion" => "2024-11-01" "aid" => "102279" "copyright" => "Sociedad Española de Médicos de Atención Primaria (SEMERGEN)" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "es" => array:9 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Carta al Director</span>" "titulo" => "Ecoansiedad: impacto del cambio climático en la salud mental" "tienePdf" => "es" "tieneTextoCompleto" => "es" "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Ecoanxiety: Impact of climate change on mental health" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "M. Regalado Chamorro, A. Medina Gamero" "autores" => array:2 [ 0 => array:2 [ "nombre" => "M." "apellidos" => "Regalado Chamorro" ] 1 => array:2 [ "nombre" => "A." "apellidos" => "Medina Gamero" ] ] ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1138359324000893?idApp=UINPBA00004N" "url" => "/11383593/0000005000000008/v8_202409230945/S1138359324000893/v8_202409230945/es/main.assets" ] "en" => array:14 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Letter to the Editor</span>" "titulo" => "Tirbanibulin ointment: A new effective and safe treatment of recalcitrant viral warts" "tieneTextoCompleto" => true "saludo" => "Dear Editor," "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "M. Mansilla-Polo, C. Abril-Pérez, D. Martín-Torregrosa" "autores" => array:3 [ 0 => array:4 [ "nombre" => "M." "apellidos" => "Mansilla-Polo" "email" => array:1 [ 0 => "miguel_yecla96@hotmail.com" ] "referencia" => array:3 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] 2 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "C." "apellidos" => "Abril-Pérez" "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] 2 => array:3 [ "nombre" => "D." "apellidos" => "Martín-Torregrosa" "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] ] "afiliaciones" => array:2 [ 0 => array:3 [ "entidad" => "Department of Dermatology, La Fe University and Polytechnic Hospital, Valencia, Spain" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Universidad de Valencia, Valencia, Spain" "etiqueta" => "b" "identificador" => "aff0010" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Tirbanibulina: un nuevo tratamiento efectivo y seguro para verrugas víricas recalcitrantes" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1374 "Ancho" => 1100 "Tamanyo" => 115923 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Initial lesion presented as a papillomatous surface papule with dermatoscopy revealing red and black dots, consistent with viral wart (a and b). At 3 months of treatment (c) and 6 months of treatment (d), no signs of recurrence were observed.</p>" ] ] ] "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">Tirbanibulin, a novel antineoplastic agent, received FDA approval in 2020 for the topical management of actinic keratosis (AK). This regulatory endorsement was substantiated by pivotal clinical investigations, encompassing phase III trials and studies in real clinical practice that underscored its efficacy and safety profile.<a class="elsevierStyleCrossRefs" href="#bib0030"><span class="elsevierStyleSup">1,2</span></a> Formulated from a synthetic analog of hemiasterlin, tirbanibulin exerts its effects through the disruption of microtubule dynamics, culminating in cell cycle arrest and apoptosis.<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">3</span></a> With its approval, a new therapeutic weapon appeared for AK and its field of cancerization, a very common pathology in primary care. However, the singularity of its mechanism of action, coupled with its relatively favorable tolerability, has prompted exploration for its potential extension into novel therapeutic applications.</p><p id="par0010" class="elsevierStylePara elsevierViewall">A 28-year-old woman, with no notable medical history sought evaluation for a viral wart (VW) located on the fingertip of her right index finger. She reported the lesion for approximately 4 years. She had undergone three cryotherapy sessions, one electrocoagulation treatment, and a topical combination of salicylic acid and 5-fluorouracil, all yielding only partial responses with subsequent relapses. Upon examination, a 0.8<span class="elsevierStyleHsp" style=""></span>cm<span class="elsevierStyleHsp" style=""></span>×<span class="elsevierStyleHsp" style=""></span>0.7<span class="elsevierStyleHsp" style=""></span>cm papule was observed proximally on the fingertip (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>a and b). Dermoscopy revealed a slightly velvety surface and fine superficial puncta consistent with a VW (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>b). Faced as refractory VW, superficial curettage followed by application of aluminum chloride to remove the surface of the wart. Ten days post-curettage, topical application of 1% tirbanibulin ointment for 5 consecutive nights was initiated. At the 3-month follow-up, the patient showed no recurrence, albeit experiencing mild dysesthesias at the application site (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>c). At the 6-month mark, no lesions were present, and the patient remained entirely asymptomatic (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>d). No adverse effects were reported during tirbanibulin treatment.</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia><p id="par0015" class="elsevierStylePara elsevierViewall">Recently, a new drug, tirbanibulin 1% ointment, has become available for the treatment of actinic keratosis (AK) and its field of cancerization. Initially, its approval was based on studies involving a 25<span class="elsevierStyleHsp" style=""></span>cm<span class="elsevierStyleSup">2</span> application on immunocompetent patients with lesions located on the head and scalp.<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">1</span></a> However, recent studies have demonstrated its potential effectiveness and safety in broader applications, such as areas exceeding 25<span class="elsevierStyleHsp" style=""></span>cm<span class="elsevierStyleSup">2</span>, different anatomical locations beyond the head and scalp, and among immunocompromised patients.<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">2</span></a> Furthermore, other authors have attempted to push the boundaries, expanding its use to other indications. Thus, recently, case series have been reported with a favorable response and an appropriate safety profile in the treatment with tirbanibulin 1% ointment for in situ squamous cell carcinoma, invasive squamous cell carcinoma, superficial basal cell carcinoma or condyloma acuminata.<a class="elsevierStyleCrossRefs" href="#bib0045"><span class="elsevierStyleSup">4,5</span></a></p><p id="par0020" class="elsevierStylePara elsevierViewall">In conclusion, we present tirbanibulin 1% ointment as a potential new therapeutic option that is effective and safe for the treatment of refractory VW. This utility opens the possibility of its use as a treatment for recalcitrant viral warts in primary care.</p><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0005">Ethics</span><p id="par0025" class="elsevierStylePara elsevierViewall">Procedures followed here were in accordance with the ethical standards of the responsible committee on human experimentation and with the Helsinki Declaration of 1975, as revised in 1983. We have not use patients’ names, initials, or hospital numbers.</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0010">Funding</span><p id="par0030" class="elsevierStylePara elsevierViewall">No specific funding was received from any bodies in the public, commercial or not-for-profit sectors to carry out the work described in this article.</p></span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0015">Authorship</span><p id="par0035" class="elsevierStylePara elsevierViewall">All authors had access to the data and played a role in writing this manuscript.</p></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0020">Authors’ contributions</span><p id="par0040" class="elsevierStylePara elsevierViewall"><ul class="elsevierStyleList" id="lis0005"><li class="elsevierStyleListItem" id="lsti0005"><span class="elsevierStyleLabel">-</span><p id="par0045" class="elsevierStylePara elsevierViewall">Miguel Mansilla-Polo and Daniel Martín-Torregrosa managed clinical treatment and procedures, contributing to the development of this paper.</p></li><li class="elsevierStyleListItem" id="lsti0010"><span class="elsevierStyleLabel">-</span><p id="par0050" class="elsevierStylePara elsevierViewall">Carlos Abril-Pérez supervised the work.</p></li></ul></p></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Informed consent</span><p id="par0055" class="elsevierStylePara elsevierViewall">Oral and written consent was obtained to publish this image.</p></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0030">Conflicts of interest</span><p id="par0060" class="elsevierStylePara elsevierViewall">The authors have declared no conflicts of interest.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:7 [ 0 => array:2 [ "identificador" => "sec0005" "titulo" => "Ethics" ] 1 => array:2 [ "identificador" => "sec0010" "titulo" => "Funding" ] 2 => array:2 [ "identificador" => "sec0015" "titulo" => "Authorship" ] 3 => array:2 [ "identificador" => "sec0020" "titulo" => "Authors’ contributions" ] 4 => array:2 [ "identificador" => "sec0025" "titulo" => "Informed consent" ] 5 => array:2 [ "identificador" => "sec0030" "titulo" => "Conflicts of interest" ] 6 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "multimedia" => array:1 [ 0 => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1374 "Ancho" => 1100 "Tamanyo" => 115923 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Initial lesion presented as a papillomatous surface papule with dermatoscopy revealing red and black dots, consistent with viral wart (a and b). At 3 months of treatment (c) and 6 months of treatment (d), no signs of recurrence were observed.</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0015" "bibliografiaReferencia" => array:5 [ 0 => array:3 [ "identificador" => "bib0030" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Phase 3 trials of tirbanibulin ointment for actinic keratosis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A. Blauvelt" 1 => "S. Kempers" 2 => "E. Lain" 3 => "T. Schlesinger" 4 => "S. Tyring" 5 => "S. Forman" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "N Engl J Med" "fecha" => "2021" "volumen" => "11" "paginaInicial" => "512" "paginaFinal" => "520" ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0035" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effectiveness, safety and satisfaction of 1% tirbanibulin ointment in the treatment of actinic keratoses: a prospective study in real clinical practice" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Mansilla-Polo" 1 => "C. Abril-Pérez" 2 => "D. Martín-Torregrosa" 3 => "J. López-Davia" 4 => "B. de Unamuno-Bustos" 5 => "I. Torres-Navarro" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Aust J Dermatol" "fecha" => "2023" "volumen" => "64" "paginaInicial" => "560" "paginaFinal" => "564" ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0040" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Tirbanibulin: review of its novel mechanism of action and how it fits into the treatment of actinic keratosis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "Y. Gilaberte" 1 => "M.T. Fernández-Figueras" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.ad.2021.07.006" "Revista" => array:7 [ "tituloSerie" => "Actas Dermosifiliogr" "fecha" => "2022" "volumen" => "113" "paginaInicial" => "58" "paginaFinal" => "66" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/35249711" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0140673611614852" "estado" => "S300" "issn" => "01406736" ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0045" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Tirbanibulin ointment to manage recurrence of superficial Basal Cell Carcinoma of the face: report of a case" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "F. Martora" 1 => "P.A. Ascierto" 2 => "M. Scalvenzi" 3 => "M. Palla" 4 => "C. Costa" 5 => "M. D’Andrea" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "tituloSerie" => "Clin Exp Dermatol" "fecha" => "2023" "volumen" => "27" "paginaInicial" => "llad334" ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0050" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Topical tirbanibulin resolves recalcitrant condyloma acuminata: Retrospective case series" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "A.Y. Moore" 1 => "K. Hurley" 2 => "S. Moore" 3 => "L. Moore" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jdcr.2023.04.011" "Revista" => array:6 [ "tituloSerie" => "JAAD Case Rep" "fecha" => "2023 26" "volumen" => "37" "paginaInicial" => "58" "paginaFinal" => "60" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/37492432" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/11383593/0000005000000008/v8_202409230945/S1138359324000881/v8_202409230945/en/main.assets" "Apartado" => array:4 [ "identificador" => "9697" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Cartas al Director" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/11383593/0000005000000008/v8_202409230945/S1138359324000881/v8_202409230945/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1138359324000881?idApp=UINPBA00004N" ]
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 July | 1 | 0 | 1 |
| 2024 June | 2 | 0 | 2 |
